| Literature DB >> 27660693 |
Ikuo Miyahisa1, Hideo Suzuki1, Atsushi Mizukami1, Yukiya Tanaka1, Midori Ono1, Mark S Hixon2, Junji Matsui1.
Abstract
Delta-5 desaturase (D5D) catalyzes the conversion from dihomo-gamma linoleic acid (DGLA) to arachidonic acid (AA). DGLA and AA are common precursors of anti- and pro-inflammatory eicosanoids, respectively, making D5D an attractive drug target for inflammatory-related diseases. Despite several reports on D5D inhibitors, their biochemical mechanisms of action (MOAs) remain poorly understood, primarily due to the difficulty in performing quantitative enzymatic analysis. Herein, we report a radioligand binding assay to overcome this challenge and characterized T-3364366, a thienopyrimidinone D5D inhibitor, by use of the assay. T-3364366 is a reversible, slow-binding inhibitor with a dissociation half-life in excess of 2.0 h. The long residence time was confirmed in cellular washout assays. Domain swapping experiments between D5D and D6D support [(3)H]T-3364366 binding to the desaturase domain of D5D. The present study is the first to demonstrate biochemical MOA of desaturase inhibitors, providing important insight into drug discovery of desaturase enzymes.Entities:
Keywords: Delta-5 desaturase; T-3364366; mechanism of action (MOA); slow-binding inhibition
Year: 2016 PMID: 27660693 PMCID: PMC5018866 DOI: 10.1021/acsmedchemlett.6b00241
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345